Sinusway
Financiado
Sinusway a revolutionary single use endoscope device for treatment of severe si...
Sinusway a revolutionary single use endoscope device for treatment of severe sinuses infection Sinusitis
Rhinosinusitis (RS) (better known as sinusitis) is a severe infection caused when the tiny air pockets around the bones of the nose are filled with germs or fluids. Sinusitis affects more than 80 million people in Europe and 803 m...
Rhinosinusitis (RS) (better known as sinusitis) is a severe infection caused when the tiny air pockets around the bones of the nose are filled with germs or fluids. Sinusitis affects more than 80 million people in Europe and 803 million around the world, making it one of the most common health problems worldwide. Sinusitis sufferers carry a huge burden of symptoms, including challenging breathing, headaches, facial pain, nasal congestions, fever and disrupted sleep all of which drastically affects their quality of life. Since thin sinus walls share a border with the surrounding tissue, sinus infection can spread beyond the border of sinuses and cause major complications to eyes, brain and even cause asthma and bone infections. Hence, proper diagnosis and management of sinusitis is essential to prevent the risk of complications. However, current drawbacks of tools available to physicians make diagnosis and management of sinusitis very difficult. Sinusway is a novel lightweight single use endoscope for patients suffering from sinusitis. Sinusway is the first one that allows the tip of the endoscope to turn sharply into lumens in the sinus and then advance in the direction of the angulation which was set, beyond the point of angulation and independently from it. This allows to reach more than 90% of the sinus area. Using an intuitive easy-to-use ergonomics, ENT physicians have full control over the direction of the advancement of the endoscope, without the need of the support from the anatomy to do so. As such, Sinusway represents a revolutionary solution to a global market expected to grow to €20.86 billion by 2022.
ver más
Duración del proyecto: 3 meses
Fecha Inicio: 2018-11-28
Fecha Fin: 2019-02-28
Fecha Fin: 2019-02-28
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-02-28
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
3NT MEDICAL LTD
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
257.68K€ |
Participante